Neutropenia - Drug Pipeline Analysis and Market Forecasts to 2016

Neutropenia - Drug Pipeline Analysis and Market Forecasts to 2016

Summary

GlobalData's pharmaceutical and healthcare report offering, “Neutropenia – Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global lung cancer market. This pharma report identifies the key trends shaping and driving the global neutropenia market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global neutropenia sector.

GlobalData estimated the global neutropenia market to grow by 4% annually for the next seven years to reach $8.6 billion in 2016. This moderate growth is primarily attributed to the increase in the uptake of biologics and the presence of strong pipeline candidates. The growth will be supported by increases in incidence and prevalence of the disease, and the high prescription rate of the currently marketed products. GlobalData determined that the global neutropenia market is moderately served by the current product options and significant scope is available to new entrants that can capture value from underserved segments. Designing highly efficacious products that will encourage physician compliance is one of key challenges of this market and could provide a significant market share for any company achieving this.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Scope

The scope of the report includes:

• Annualized global neutropenia market revenues data from 2001 to 2009, forecast for seven years to 2016.
• The geographies covered in this report are the United States (US), the Untied Kingdom (UK), Italy, Spain, Germany, France and Japan.
• Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. The key classes of mechanism of action include D-alanyl-D-alanine binders, fungal cytochrome P-450 inhibitors, Granulocyte Colony Stimulating Factor (G-CSF) binders and bone marrow stimulators.
• Analysis of the current and future market competition in the global neutropenia market. The key market players covered are Amgen, Pfizer, Maxygen, Teva Pharmaceuticals and CoGenesys (which is now a part of Teva Pharmaceuticals).
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• The key topics covered include a strategic competitor assessment, market characterization, unmet needs and the implications for the future neutropenia market.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

• Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global neutropenia market.
• Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global neutropenia market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global neutropenia market landscape? – Identify, understand and capitalize.

1 Table of contents 

1.1 List of Tables 

1.2 List of Figures 

2 Neutropenia Market: Market Characterization 

2.1 Market Overview 

2.2 Neutropenia Market Size 

2.3 Neutropenia Market forecast and CAGR 

2.4 Neutropenia Market Drivers 

2.4.1 Steady Increase in the Prevalence Population 

2.4.2 Increase in the Uptake of Biologics 

2.4.3 Increase in the Prescription Population 

2.4.4 Increase in Conditions Such as Cancer and Cardiovascular Events will Increase the Prevalence of drug induced Neutropenia 

2.5 Neutropenia Market Restraints 

2.5.1 Low Diagnosis Rate 

2.5.2 Patent Expiries of Major Blockbuster Drugs Including Neupogen and Neulasta 

2.5.3 Opening up of US market to biosimilars and generics 

2.6 Opportunity and Unmet Need 

2.6.1 Key Takeaway 

3 Neutropenia Market: Competitive Assessment 

3.1 Overview 

3.2 Strategic Competitor Assessment 

3.3 Product Profile for the Marketed Drugs for Neutropenia 

3.3.1 Neulasta (Pegfilgrastim) 

3.3.2 Neupogen 

3.4 Product Profile for Off-Label Drugs for Neutropenia 

3.4.1 Leukine 

3.5 Key Takeaway 

4 Neutropenia Market: Pipeline Assessment 

4.1 Overview 

4.2 Strategic Pipeline Assessment 

4.2.1 Technology Trends Analytic Framework 

4.3 Profile of the Promising Pipeline Molecules in Clinical Development 

4.3.1 Voriconazole 

4.3.2 Linezolid 

4.3.3 Neugranin 

4.3.4 Maxy-G34 

4.4 Neutropenia - Clinical Pipeline by Mechanism of Action 

4.5 Neutropenia Pipeline - Pipeline by Clinical Phases of Development 

4.5.1 Neutropenia Market - Phase III Clinical Pipeline 

4.5.2 Neutropenia Market - Phase II Clinical Pipeline 

4.5.3 Neutropenia Market - Pre Clinical Pipeline 

4.5.4 Neutropenia Market - Terminated Pipeline Molecules 

4.5.5 Neutropenia Market - Approved Pipeline Molecules 

4.6 Key takeaway 

5 Neutropenia Market: Implications for Future Market Competition 

6 Neutropenia Market: Future Players in Neutropenia Market 

6.1 Introduction 

6.2 Maxygen 

6.2.1 Company Overview 

6.2.2 Business Description 

6.2.3 Hematology Disorder Portfolio 

6.3 Pfizer 

6.3.1 Company Overview 

6.3.2 Financial Performance 

6.3.3 Business Description 

6.3.4 Hematology Disorder Portfolio 

6.4 Teva Pharmaceutical Industries Limited 

6.4.1 Company Overview 

6.4.2 Financial Performance 

6.4.3 Business Description 

6.4.4 CoGenesys- The company acquired by Teva Pharmceuticals 

6.4.5 Blood Disorder Portfolio 

7 Neutropenia Market: Appendix 

7.1 Definitions 

7.2 Acronyms 

7.3 Research Methodology 

7.3.1 Coverage 

7.3.2 Secondary Research 

7.3.3 Forecasting 

7.3.4 Primary Research 

7.3.5 Expert Panel Validation 

7.4 Contact Us 

7.5 Disclaimer 

7.6 Sources